论文部分内容阅读
目的探讨胃癌化疗治疗中,当归补血汤联合参芪扶正注射液辅助治疗对G-17、脂联素及预后的影响。方法选取2015年1月~2016年3月在我院接受化疗治疗的胃癌患者66例作为研究对象,随机将其分为对照组和研究组,各33例,其中仅接受常规化疗治疗者为对照组,接受常规护化疗治疗联合当归补血汤及参芪扶正注射液辅助治疗者为研究组。分析两组G-17及脂联素变化情况,并对比两组近期疗效。结果在6个疗程化疗结束后,研究组G-1低于对照组,脂联素高于对照组,差异有统计学意义(P<0.05)。同时,研究组治疗总控制率高于对照组,差异有统计学意义(P<0.05),而两组Ⅱ及以上不良反应比较,差异无统计学意义(P>0.05)。结论当归补血汤联合参芪扶正注射液可在不增加治疗不良反应发生率的同时,有效的改善接受胃癌化疗治疗的G-17、脂联素水平及疗效。
Objective To investigate the effect of Dangguibuxuetang combined with Shenqi Fuzheng injection on G-17, adiponectin and prognosis in gastric cancer chemotherapy. Methods Sixty-six patients with gastric cancer undergoing chemotherapy in our hospital from January 2015 to March 2016 were selected and randomly divided into control group and study group, with 33 cases in each group, of whom only conventional chemotherapy treatment was control Group, receiving routine chemotherapy and chemotherapy combined with Dangguibuxuetang and Shenqi Fuzheng injection adjuvant therapy for the study group. Analysis of two groups of G-17 and adiponectin changes, and compared the two groups of short-term efficacy. Results After 6 courses of chemotherapy, G-1 in study group was lower than that in control group, adiponectin was higher than that in control group, the difference was statistically significant (P <0.05). At the same time, the total control rate of study group was higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference between the two groups in adverse reaction of Ⅱ and above (P> 0.05). Conclusion Dangguibuxuetang combined with Shenqi Fuzheng injection can effectively improve the level of G-17, adiponectin and efficacy of gastric cancer chemotherapy without increasing the incidence of adverse reactions.